-+ 0.00%
-+ 0.00%
-+ 0.00%

Aptadir closes EUR 40 million seed round backed by Angelini Ventures

PUBT·09/30/2026 08:44:04
Aptadir closes EUR 40 million seed round backed by Angelini Ventures
  • Aptadir Therapeutics raised EUR 40 million in a seed round to advance RNA inhibitor medicines targeting gene silencing.
  • Angelini Ventures participated via a direct investment; 4BIO Capital led the financing.
  • Proceeds target Aptadir’s lead program, CAP1-FMR1, for Fragile X syndrome, alongside a broader pipeline of investigational RNA therapeutics.
  • Aptadir is developing DNMTs Interacting RNAs designed to block aberrant DNA methylation at single genes and restore gene expression.
  • The science originated at Beth Israel Deaconess Medical Center, Italy’s National Research Council, and the Cancer Science Institute of Singapore.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Angelini Ventures SpA published the original content used to generate this news brief on September 29, 2026, and is solely responsible for the information contained therein.